Investors

Breaking News:

Abivax publishes review in DDT on mechanism of action and transformative potential of ABX464 as therapy for inflammatory diseases:
https://abivax.gcs-web.com/news-releases/news-release-details/abivax-publishes-review-drug-discovery-today-mechanism-action

Share Profile

Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.

  • ISIN code: FR0012333284
  • Symbol: ABVX
  • ICB Classification: Healthcare 4000/ Biotechnology 4573
  • Market: Euronext Paris-Compartment C
  • Type of Listing: continuous
  • Number of shares: 14,316,672 as of November 30, 2020
  • Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
  • Eligible to French PEA PME

Analysts

LifeSci Capital Alpha Series:

Adam Evertts & David Sherman

Bryan, Garnier & Co:

Eric Le Berrigaud & Jean-Jacques Le Fur

goetzpartners securities:

Chris Redhead

Degroof Petercam:

Benoit Louage

Kepler Cheuvreux:

Damien Choplain

Portzamparc:

Christophe Dombu

Investor Contact

Chris Maggos LifeSci Advisors Chris@lifesciadvisors.com +41 79 367 6254